Actively Recruiting
Prostate Cancer Vaccines
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2025-07-20
30
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Tumor antigens are protein fragments produced by cancer cells carrying genetic mutations, and many tumor antigens are similar to normal protein antigens, making them unrecognizable by the immune system. Many tumor vaccines are prepared based on a single tumor antigen. This study is based on multiple target antigens using tumor lysates or synthetic peptides. The immune modulation by dendritic-cell (DC)-based cancer vaccines consists of genetically modified DCs to activate T cells to target cancer cells. The study is based on an advanced cancer vaccine technology, which aims to evaluate the safety and potential benefit of the novel immunomodulatory prostate cancer DC vaccines.
CONDITIONS
Official Title
Prostate Cancer Vaccines
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed adenocarcinoma of the prostate
- ECOG performance status 0-1
- Life expectancy of at least 12 weeks
- White blood cell count of at least 3,500/µL
- Platelet count of at least 100,000/µL
- Hemoglobin level of at least 10.0 g/dL
- Creatinine level of 2.0 mg/dL or below
- Alkaline phosphatase level no higher than 2.5 times the upper limit of normal
- AST level no higher than 2.5 times the upper limit of normal
- Fertile patients must use effective contraception
- Willingness to provide blood samples for research
- Ability to complete questionnaires alone or with assistance
- Ability to undergo leukapheresis
- No known immunodeficiency
- No other malignancy within the past 5 years except treated basal cell or squamous cell carcinoma of the skin
- No concurrent serious illness
- No history of positive PPD skin test
- Negative tests for HIV and Hepatitis C virus (HCV)
You will not qualify if you...
- Using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection
- History of autoimmune diseases or illnesses requiring long-term hormone or immunosuppressive drug use
- History of allergies to immune cells or adjuvants in cellular products
- Active infection with fever
- Neutropenia lasting more than 10 days and difficult to correct
- Uncontrolled infections with bacteria, fungi, or viruses
- Infection with HIV or active Hepatitis B or C virus
- Severe organ failure of heart, liver, kidney, or lung
- Previous treatment with cell therapy products deemed unsuitable by experts
- Any condition that may increase risk to the participant or affect study results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here